Literature DB >> 23429006

Persistence at one year of age of antigen-induced cellular immune responses in preterm infants vaccinated against whooping cough: comparison of three different vaccines and effect of a booster dose.

Françoise Vermeulen1, Violette Dirix, Virginie Verscheure, Eliane Damis, Danièle Vermeylen, Camille Locht, Françoise Mascart.   

Abstract

Due to their high risk of developing severe Bordetella pertussis (Bp) infections, it is recommended to immunize preterm infants at their chronological age. However, little is known about the persistence of their specific immune responses, especially of the cellular responses recognized to play a role in protection. We compared here the cellular immune responses to two major antigens of Bp between three groups of one year-old children born prematurely, who received for their primary vaccination respectively the whole cell vaccine Tetracoq(®) (TC), the acellular vaccine Tetravac(®) (TV), or the acellular vaccine Infanrix-hexa(®) (IR). Whereas most children had still detectable IFN-γ responses at one year of age, they were lower in the IR-vaccinated children compared to the two other groups. In contrast, both the TV- and the IR-vaccinated children displayed higher Th2-type immune responses, resulting in higher antigen-specific IFN-γ/IL-5 ratios in TC- than in TV- or IR-vaccinated children. The IFN-γ/IL-5 ratio of mitogen-induced cytokines was also lower in IR- compared to TC- or TV-vaccinated children. No major differences in the immune responses were noted after the booster compared to the pre-booster responses for each vaccine. The IR-vaccinated children had a persistently low specific Th1-type immune response associated with high specific Th2-type immune responses, resulting in lower antigen-specific IFN-γ/IL-5 ratios compared to the two other groups. We conclude that antigen-specific cellular immune responses persisted in one year-old children born prematurely and vaccinated during infancy at their chronological age, that a booster dose did not significantly boost the cellular immune responses, and that the Th1/Th2 balance of the immune responses is modulated by the different vaccines.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429006     DOI: 10.1016/j.vaccine.2013.02.004

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

Review 1.  Immune persistence after pertussis vaccination.

Authors:  Zhiyun Chen; Qiushui He
Journal:  Hum Vaccin Immunother       Date:  2017-01-03       Impact factor: 3.452

Review 2.  What Is Wrong with Pertussis Vaccine Immunity? The Problem of Waning Effectiveness of Pertussis Vaccines.

Authors:  Nicolas Burdin; Lori Kestenbaum Handy; Stanley A Plotkin
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-12-01       Impact factor: 10.005

3.  Tdap vaccine effectiveness in adolescents during the 2012 Washington State pertussis epidemic.

Authors:  Anna M Acosta; Chas DeBolt; Azadeh Tasslimi; Melissa Lewis; Laurie K Stewart; Lara K Misegades; Nancy E Messonnier; Thomas A Clark; Stacey W Martin; Manisha Patel
Journal:  Pediatrics       Date:  2015-05-04       Impact factor: 7.124

Review 4.  Hexavalent vaccines in preterm infants: an update by Italian Society of Pediatric Allergy and Immunology jointly with the Italian Society of Neonatology.

Authors:  E Chiappini; C Petrolini; C Caffarelli; M Calvani; F Cardinale; M Duse; A Licari; S Manti; A Martelli; D Minasi; M Miraglia Del Giudice; G B Pajno; C Pietrasanta; L Pugni; M A Tosca; F Mosca; G L Marseglia
Journal:  Ital J Pediatr       Date:  2019-11-19       Impact factor: 2.638

5.  Proper pertussis vaccination will probably not increase vaccination coverage: a case-control study.

Authors:  R Solano; A V Sanchez-Callejas; M I Alvarez-Ibañez; M Sandiumenge-Durán; M I Fernández-San-Martín
Journal:  Epidemiol Infect       Date:  2019-08-20       Impact factor: 2.451

Review 6.  Rediscovering Pertussis.

Authors:  Manuela Zlamy
Journal:  Front Pediatr       Date:  2016-06-08       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.